Cross-institution positioning
Jul 29, 2026Strong institutional reduction. 1 reducing, 3 exited across 4 comparable institutions.
Source: Schedule 13 researchGossamer Bio, Inc.
Latest stored close $9.88 as of Oct 8, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Strong institutional reduction. 1 reducing, 3 exited across 4 comparable institutions.
Source: Schedule 13 research0 increased/new, 2 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsRecent Forms 3/4/5 activity is available, with no non-amendment non-derivative SEC-coded P/S transactions in the rolling 90-day window. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/512 non-amendment material events in the last 90 days; 2 capital-related filing/events (2 equity-related, 0 debt-related); Latest classified evidence: Other event. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataRevenue -19.6% YoY; Net income +144.2% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 60% through its reported 52-week range; +226.4% over one year.
Source: Stored historical price seriesFiled Jul 29, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | Nathan Steven D | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 10.0K | $0.00 | Direct | Sep 25, 2026 |
| Sep 23, 2026 | Cox Russell J. | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 10.0K | $0.00 | Direct | Sep 25, 2026 |
| Sep 23, 2026 | Quisel John D | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 10.0K | $0.00 | Direct | Sep 25, 2026 |
| Sep 23, 2026 | Drynan Skye | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 10.0K | $0.00 | Direct | Sep 25, 2026 |
| Sep 23, 2026 | Ciongoli Gregory Austin | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 30.0K | $0.00 | Direct | Sep 25, 2026 |
| Sep 23, 2026 | Daniel Thomas O | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 10.0K | $0.00 | Direct | Sep 25, 2026 |
| Sep 23, 2026 | Milligan Sandra | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 10.0K | $0.00 | Direct | Sep 25, 2026 |
| Aug 24, 2026 | Hasnain Faheem | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 5.8M | $0.00 | Direct | Aug 26, 2026 |
| Aug 24, 2026 | Hasnain Faheem | AGrant, award, or other acquisition · derivative | Pre-Funded Warrant (Right to Buy) | 166 | $1,000.00 | Indirect | Aug 26, 2026 |
| Aug 24, 2026 | Christian Waage | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 2.9M | $0.00 | Direct | Aug 26, 2026 |
| Aug 24, 2026 | Giraudo Bryan | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 5.8M | $0.00 | Direct | Aug 26, 2026 |
| Aug 24, 2026 | Giraudo Bryan | AGrant, award, or other acquisition · derivative | Pre-Funded Warrant (Right to Buy) | 25 | $1,000.00 | Indirect | Aug 26, 2026 |
| Aug 24, 2026 | Smith Robert Paul JR | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 5.8M | $0.00 | Direct | Aug 26, 2026 |
| Aug 24, 2026 | Peterson Caryn | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 5.8M | $0.00 | Direct | Aug 26, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Sep 28, 2026 | 8-K | 8.01 | Other event | — | Filing |
| Sep 23, 2026 | 8-K | 8.01 | Other event | — | Filing |
| Sep 16, 2026 | 8-K | 5.02, 9.01 | Director or executive change; Financial statements / exhibits | — | Filing |
| Sep 11, 2026 | 8-K | 3.03, 5.03, 8.01, 9.01 | Material modification of security-holder rights; Charter or bylaw change; Other event; Financial statements / exhibits | Equity | Filing |
| Sep 9, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Sep 3, 2026 | 8-K | 5.03, 9.01 | Charter or bylaw change; Financial statements / exhibits | — | Filing |
| Aug 26, 2026 | 8-K | 5.03, 9.01 | Charter or bylaw change; Financial statements / exhibits | — | Filing |
| Aug 21, 2026 | 8-K | 1.01, 3.02, 5.03, 7.01, 9.01 | Material definitive agreement; Unregistered sale of equity securities; Charter or bylaw change; Regulation FD disclosure; Financial statements / exhibits | Equity | Filing |
| Aug 13, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jul 27, 2026 | 8-K | 1.01, 1.02, 2.02, 7.01, 8.01, 9.01 | Material definitive agreement; Termination of material agreement; Results of operations / financial condition; Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Jul 15, 2026 | 8-K | 5.02, 5.03, 5.07, 9.01 | Director or executive change; Charter or bylaw change; Shareholder vote results; Financial statements / exhibits | — | Filing |
| Jul 1, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $9.2M | -19.6% |
| Ended Jun 30, 2025 | $11.5M | — |
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| BlackRock CIK0002012383 | Jun 30, 2026 observed Jul 29, 2026 filed · 29d Schedule 13G amendment | Reported reduction | 4.9M -10.2M | 12.00% 0.00 pts | $0.17 | $0.21 | $9.88 |
| Vanguard Group CIK0000102909 | Mar 13, 2026 observed Mar 27, 2026 filed · 14d Schedule 13G amendment | Exit below reporting threshold | 0 -11.4M | 0.00% -5.02 pts | $0.44 | $0.35 | $9.88 |
| BlackRock CIK0002012383 | Dec 31, 2025 observed Jan 21, 2026 filed · 21d Schedule 13G amendment | Reported accumulation | 15.1M +2.9M | 12.00% +6.70 pts | $3.10 | $2.74 | $9.88 |
Compare GOSS with other securities showing similar institutional activity or recent accumulation across several tracked institutions.